Cancer Genetics falls on delay of quarterly report

Interpace Biosciences

15/11/2019 18:23

** Diagnostic co's  CGIX.O  shares slide 9.5% to $2.49 
    ** Co says cannot file Q3 report by due date (http://bit.ly/2OdLMe9)
    ** Co attributes delay to resources dedicated to the sale of
its clinical laboratory business and its biopharma services
business (http://bit.ly/2NOz4DE)  urn:newsml:reuters.com:*:nL4N24H2GC
    ** Says management has been preoccupied with closing of the
transactions, adds that it lost many employees due to the sale
of its biopharma business, and has to rely on fewer finance
employees
    ** Previously, co had delayed earnings reports of its first
two qtrs of 2019 as well as the annual earnings report of 2018
    ** Stock down 62.1% YTD as of Thursday's close
    

 (Reporting by Ruhi Soni)
 ((Ruhi.Soni@thomsonreuters.com;))